The JOURNAL OF CLINICAL PSYCHIATRY is a premier publication dedicated to advancing the understanding and treatment of psychiatric disorders. Established in 1978 and published by Physicians Postgraduate Press, this esteemed journal provides a vital platform for researchers, clinicians, and mental health professionals to share innovative findings and evidence-based practices in psychiatry. With an impressive impact factor and recognized as a Q1 journal in both Medicine (miscellaneous) and Psychiatry and Mental Health, the journal ranks among the top in its field, sitting at 96th out of 567 in Scopus rankings, placing it in the 83rd percentile. The journal's commitment to high-quality, peer-reviewed articles facilitates the dissemination of knowledge crucial for advancing clinical practices and improving patient outcomes. Access to its latest research is offered through institutional subscriptions, making it an essential resource for anyone involved in the mental health sector, from seasoned practitioners to aspiring students.

Therapeutic Advances in Chronic Disease is a distinguished open-access journal published by SAGE Publications Ltd, with a focus on innovative research and clinical practices addressing chronic diseases—a field increasingly relevant in today's healthcare landscape. Since its inception in 2010, the journal has committed itself to disseminating high-quality research that informs both theory and practice. With an impressive impact factor and ranked Q1 in Medicine (miscellaneous) in 2023, this journal boasts recognition as one of the top-tier publications in the medical community, placing it in the 79th percentile among its peers. Accessible since 2019, it aims to bridge the gap between cutting-edge research and its application in improving patient outcomes, inviting contributions from researchers, clinicians, and health professionals. The journal's comprehensive scope encompasses various aspects of chronic disease management, making it an invaluable resource for those seeking to advance their understanding of this critical field.

PSYCHOPHARMACOLOGY is a leading peer-reviewed journal specializing in the field of pharmacology, specifically focusing on the effects of drugs on behavior, cognition, and emotion. Published by Springer, this esteemed journal has established itself as a pivotal resource for researchers and professionals since its inception in 1959, maintaining its relevance and rigor in the ever-evolving landscape of psychopharmacological research. With an impressive impact factor and ranking in the top quartile (Q1) of the Pharmacology category in 2023, it consistently publishes high-quality studies that contribute to both academic inquiry and clinical practice. The journal's scope includes original research, theoretical papers, and reviews, fostering a multidisciplinary dialogue among psychologists, psychiatrists, pharmacologists, and neuroscientists. As the field of psychopharmacology continues to grow, PSYCHOPHARMACOLOGY remains dedicated to disseminating innovative findings, operationalizing complex concepts, and enhancing the understanding of drug mechanisms and their implications for mental health. This commitment to excellence positions PSYCHOPHARMACOLOGY as an indispensable tool for those seeking to advance their knowledge and research in pharmacology.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a pivotal peer-reviewed journal in the fields of pharmacology and psychiatry. Established in 1986, it has garnered a prominent reputation with a 2023 impact factor placing it in the Q2 category for both Pharmacology and Psychiatry and Mental Health. With an impressive Scopus ranking of #227 in the Psychiatry and Mental Health category and #114 in Pharmacology, it serves as an essential platform for researchers seeking to disseminate critical findings on psychopharmacological interventions and their clinical efficacy. The journal’s rigorous peer-review process ensures that only high-quality research is published, making it a trusted resource for professionals and students alike. By focusing on the latest advancements and evidence-based practices, the INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY contributes significantly to the understanding of mental health treatments, fostering ongoing dialogue and innovation in the discipline.

British Journal of Psychiatry, published by Cambridge University Press, stands as a pivotal resource in the realm of mental health and psychiatry. With an impressive impact reflected in its Q1 classifications in both Medicine (miscellaneous) and Psychiatry and Mental Health, this esteemed journal ranks 23rd out of 567 in its field according to Scopus, achieving an exceptional 96th percentile. Since its inception in 1963, the journal has continued to push the boundaries of research and discourse, serving as a platform for groundbreaking studies that enhance our understanding of psychiatric conditions and promote effective therapeutic strategies. Though it does not operate with an open-access model, the British Journal of Psychiatry remains an essential publication for researchers, clinicians, and students alike, offering in-depth insights and innovative findings that are crucial for navigating the complexities of mental health.

Neurology Research International, published by HINDAWI LTD, is an esteemed open access journal that has been serving the neurology community since 2010. With its ISSN 2090-1852 and E-ISSN 2090-1860, this journal aims to foster knowledge dissemination and facilitate dialogue surrounding key issues in neurology and clinical neuroscience, making it a vital resource for researchers, clinicians, and students alike. It operates from the United States, with its administrative hub located in London, England. As of 2023, the journal has been positioned in the Q3 category for both neurology and clinical neurology, reflecting its commitment to advancing research within these critical fields. With a current Scopus rank of #216/400 in clinical neurology and a #113/192 in neuroscience, and a converged publication timeline from 2010 to 2024, Neurology Research International is dedicated to promoting high-quality research that addresses contemporary challenges and innovations in neurological science. By offering open access since its inception, it ensures that cutting-edge research is freely available, aligning with the global push towards accessible scientific communication.

Endocrine Metabolic & Immune Disorders-Drug Targets, published by Bentham Science Publishers, is a premier journal focused on the intricate interplay between endocrinology, metabolism, and immune response, with a particular emphasis on drug targets. Established in 2006 and set to continue its influence until 2024, this journal serves as a crucial platform for researchers and professionals to communicate significant advances in understanding metabolic and immune disorders, making it an invaluable resource in the realms of Endocrinology and Immunology. With an impact factor positioned within the Q3 category for both Endocrinology, Diabetes and Metabolism, and Immunology and Allergy as of 2023, the journal stands at the crossroads of critical research and clinical application, facilitating ongoing dialogue among the scientific community. Although currently not open access, its dedication to high-quality peer-reviewed articles ensures that cutting-edge research remains accessible to those invested in enhancing therapeutic strategies. For researchers and practitioners alike, Endocrine Metabolic & Immune Disorders-Drug Targets is an essential conduit for the latest findings that can influence treatment paradigms and bolster the understanding of complex biological systems.

Rivista di Psichiatria, published by PENSIERO SCIENTIFICO EDITORE, stands as a significant contributor to the field of Psychiatry and Mental Health since its inception in 1975. With an ISSN of 0035-6484 and an E-ISSN of 2038-2502, this esteemed journal offers a platform for rigorous academic discourse and cutting-edge research, helping to shape contemporary psychiatric practices and theories. Currently holding a Q2 designation in Psychiatry and Mental Health based on the 2023 category quartiles, and ranking #197 out of 567 in Scopus, it reflects a commendable 65th percentile among its peers. The journal welcomes contributions that encompass a broad range of topics related to mental health, encouraging contributions from a multidisciplinary approach, which aids in its goal of advancing the understanding and application of psychiatric science. While it is a traditional journal without Open Access options, access to its valuable content can support researchers, clinicians, and students in their pursuit of knowledge and innovation within the field. Situated in Rome, Italy, at VIA SAN GIOVANNI VALDARNO 8, ROME 00138, the journal continues to enhance its rich legacy, promoting the exchange of ideas and fostering collaboration amongst practitioners and scholars alike.

HAEMOPHILIA is a leading peer-reviewed journal published by Wiley, dedicated to advancing research and clinical practices in the fields of hematology and genetics. With an impressive Impact Factor and recognition within the Q1 category for Genetics (clinical), Hematology, and Medicine (miscellaneous), this journal presents a unique platform for the dissemination of high-quality research from 1995 to the present. Researchers in these dynamic fields will find invaluable insights through original articles, systematic reviews, and clinical trials, all aimed at improving therapeutic strategies and patient outcomes. Although it operates on a subscription basis, HAEMOPHILIA's commitment to excellence is reflected in its Scopus rankings, where it stands in the 74th percentile for hematology and the 71st percentile for clinical genetics. As an essential resource for academics, healthcare professionals, and students, HAEMOPHILIA plays a pivotal role in fostering innovation and collaboration within the global medical community.

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.